I believe they have increased their sales force, which may account for increased staff costs. Obviously, they will want to expand their USA exposure now that they have FDA approval. I think it takes time to negotiate sales contracts with hospitals, so some patience required, but looks like they will get a steady stream of business.
AVP
acuron limited
announcement, page-3
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)